Challenges Associated with Tyrosine Kinase Inhibitor Therapy for Metastatic Thyroid Cancer

被引：56

作者：

Cabanillas, Maria E. ^{[1
]}

Hu, Mimi I. ^{[1
]}

Durand, Jean-Bernard ^{[2
]}

Busaidy, Naifa L. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Cardiol, Houston, TX 77030 USA

来源：

JOURNAL OF THYROID RESEARCH | 2011年 / 2011卷

关键词：

D O I：

10.4061/2011/985780

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Tyrosine kinase inhibitors (TKIs) which target angiogenesis are promising treatments for patients with metastatic medullary and differentiated thyroid cancers. Sorafenib, sunitinib, and pazopanib are commercially available drugs which have been studied in these diseases. Vandetanib is the first drug approved in the United States for treatment of medullary thyroid cancer. These TKIs are used as chronic therapies, and therefore it is imperative to understand the adverse event profile in order to avoid excessive toxicity and maintain patients on therapy as long as it proves beneficial. Here we review common toxicities, management of these, and other challenging situations that arise when using TKIs in patients with thyroid cancer.

引用

页数：9

共 43 条

[1]

American Cancer Society, 2010, CANC FACTS FIG

[2] Keratoacanthomas and Squamous Cell Carcinomas in Patients Receiving Sorafenib [J].

Arnault, Jean Philippe ;

Wechsler, Janine .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (23) :E59-E61

[3] Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study [J].

Bible, Keith C. ;

Suman, Vera J. ;

Molina, Julian R. ;

Smallridge, Robert C. ;

Maples, William J. ;

Menefee, Michael E. ;

Rubin, Joseph ;

Sideras, Kostandinos ;

Morris, John C., III ;

McIver, Bryan ;

Burton, Jill K. ;

Webster, Kevin P. ;

Bieber, Carolyn ;

Traynor, Anne M. ;

Flynn, Patrick J. ;

Goh, Boon Cher ;

Tang, Hui ;

Ivy, Susan Percy ;

Erlichman, Charles .

LANCET ONCOLOGY, 2010, 11 (10) :962-972

[4]

BOUDIER HAJS, 1992, J HYPERTENS, V10, pS147

[5] Treatment with Tyrosine Kinase Inhibitors for Patients with Differentiated Thyroid Cancer: the M. D. Anderson Experience [J].

Cabanillas, Maria E. ;

Waguespack, Steven G. ;

Bronstein, Yulia ;

Williams, Michelle D. ;

Feng, Lei ;

Hernandez, Mike ;

Lopez, Adriana ;

Sherman, Steven I. ;

Busaidy, Naifa L. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (06) :2588-2595

[6] Phase II Study of Daily Sunitinib in FDG-PET-Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation [J].

Carr, Laurie L. ;

Mankoff, David A. ;

Goulart, Bernardo H. ;

Eaton, Keith D. ;

Capell, Peter T. ;

Kell, Elizabeth M. ;

Bauman, Julie E. ;

Martins, Renato G. .

CLINICAL CANCER RESEARCH, 2010, 16 (21) :5260-5268

[7] Cardiomyocyte PDGFR-β signaling is an essential component of the mouse cardiac response to load-induced stress [J].

Chintalgattu, Vishnu ;

Ai, Di ;

Langley, Robert R. ;

Zhang, Jianhu ;

Bankson, James A. ;

Shih, Tiffany L. ;

Reddy, Anilkumar K. ;

Coombes, Kevin R. ;

Daher, Iyad N. ;

Pati, Shibani ;

Patel, Shalin S. ;

Pocius, Jennifer S. ;

Taffet, George E. ;

Buja, L. Maximillian ;

Entman, Mark L. ;

Khakoo, Aarif Y. .

JOURNAL OF CLINICAL INVESTIGATION, 2010, 120 (02) :472-484

[8] Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib [J].

Chu, Tammy F. ;

Rupnick, Maria A. ;

Kerkela, Risto ;

Dallabrida, Susan M. ;

Zurakowski, David ;

Nguyen, Lisa ;

Woulfe, Kathleen ;

Pravda, Elke ;

Cassiola, Flavia ;

Desai, Jayesh ;

George, Suzanne ;

Morgan, Jeffrey A. ;

Harris, David M. ;

Ismail, Nesreen S. ;

Chen, Jey-Hsin ;

Schoen, Frederick J. ;

Van den Abbeele, Annick D. ;

Demetri, George D. ;

Force, Thomas ;

Chen, Ming Hui .

LANCET, 2007, 370 (9604) :2011-2019

[9] Phase II trial of sunitinib in medullary thyroid cancer (MTC) [J].

De Souza, J. A. ;

Busaidy, N. ;

Zimrin, A. ;

Seiwert, T. Y. ;

Villaflor, V. M. ;

Poluru, K. B. ;

Reddy, P. L. ;

Nam, J. ;

Vokes, E. E. ;

Cohen, E. E. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

[10] Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases [J].

Eremina, V ;

Sood, M ;

Haigh, J ;

Nagy, A ;

Lajoie, G ;

Ferrara, N ;

Gerber, HP ;

Kikkawa, Y ;

Miner, JH ;

Quaggin, SE .

JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (05) :707-716

← 1 2 3 4 5 →